Mehjabin Parkar, MD
Family Medicine · Sugar Land, TXNPI 1508068438
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 277 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations.
Across 277 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$788
- Lilly USA, LLC$572
- Nestle Healthcare Nutrition Inc.$415
- AbbVie$387
- AstraZeneca$363
- Bayer$335
- plus $2K from 32 others
Across 4 payments — averaging $961,812 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$3.8M
What the payments were for
- Food & beverage$5,216100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 48 | $788 |
| Lilly USA, LLC | 32 | $572 |
| Nestle Healthcare Nutrition Inc. | 20 | $415 |
| AbbVie | 20 | $387 |
| AstraZeneca | 20 | $363 |
| Bayer | 17 | $335 |
| Amgen | 18 | $317 |
| Boehringer Ingelheim | 12 | $261 |
| Pfizer | 11 | $206 |
| Aimmune Therapeutics, Inc. | 10 | $165 |
| Zynex Medical, Inc. | 1 | $144 |
| Merck | 8 | $134 |
| GSK | 4 | $118 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $115 |
| Eisai Inc. | 5 | $93 |
| Kowa Pharmaceuticals America, Inc. | 5 | $75 |
| Abbott | 3 | $68 |
| Sumitomo Pharma America, Inc. | 3 | $57 |
| Corcept Therapeutics | 3 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Phathom Pharmaceuticals, Inc. | 2 | $50 |
| Sanofi Pasteur Inc. | 2 | $49 |
| Shield Therapeutics Inc | 2 | $43 |
| Novartis | 3 | $42 |
| Exact Sciences | 2 | $40 |
| Melinta Therapeutics, LLC | 3 | $38 |
| Optinose US, Inc. | 1 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Seqirus USA Inc | 1 | $27 |
| Boston Scientific | 1 | $24 |
| Astellas Pharma US Inc | 1 | $19 |
| Phadia US Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Cumberland Pharmaceuticals, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Althera Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nexwave$144
How this compares
$5,216 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 104 | $110,040 |
| EliquisApixaban | 143 | $103,328 |
| OzempicSemaglutide | 75 | $90,638 |
| MounjaroTirzepatide | 57 | $64,376 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 16 | $60,805 |
| JanuviaSitagliptin Phosphate | 37 | $52,643 |
| XareltoRivaroxaban | 38 | $29,216 |
| FarxigaDapagliflozin Propanediol | 33 | $21,338 |
| KerendiaFinerenone | 27 | $21,103 |
| TrulicityDulaglutide | 15 | $19,100 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $18,109 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $18,025 |
| LinzessLinaclotide | 20 | $16,575 |
| TradjentaLinagliptin | 14 | $13,153 |
| EntrestoSacubitril/Valsartan | 14 | $10,945 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $261 | $123,193118 claims |
| PfizerEliquis | $206 | $103,328143 claims |
| Novo NordiskOzempic | $788 | $90,63875 claims |
| Lilly USA, LLCMounjaro, Trulicity | $572 | $83,47672 claims |
| MerckJanuvia | $134 | $52,64337 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $363 | $33,60761 claims |
| Johnson & JohnsonXarelto | $15 | $29,21638 claims |
| BayerKerendia | $335 | $21,10327 claims |
| AbbVieLinzess, Synthroid | $387 | $19,74252 claims |
| GSKTrelegy Ellipta | $118 | $18,02522 claims |
| NovartisEntresto | $42 | $10,94514 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $10,32821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Sugar Land
- Anne Marie Ponce de LeonSugar Land$109K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.